NVCR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Given the user's beginner investment knowledge, long-term strategy, and available capital, Novocure Ltd (NVCR) is not a strong buy at the moment. The company's financial performance shows declining profitability, and while there is some positive sentiment from analysts, the technical indicators and options data do not suggest a compelling entry point. A hold is recommended until clearer positive catalysts emerge.
The MACD is positive and contracting, indicating a potential weakening of bullish momentum. RSI is neutral at 60.047, and moving averages are converging, showing no strong trend. The stock is trading near its R1 resistance level of 12.939, suggesting limited immediate upside potential.
Analysts from H.C. Wainwright raised the price target to $47 following FDA approval of Optune Pax for pancreatic cancer treatment. This indicates potential long-term growth opportunities.
Gross margin also dropped by 4.33%, indicating operational challenges. Additionally, no recent insider or hedge fund activity suggests a lack of strong institutional confidence.
In Q4 2025, revenue increased by 8.11% YoY to $174.35 million. However, net income dropped significantly to -$24.5 million, and EPS fell to -0.22. Gross margin declined to 75.82%, reflecting operational inefficiencies.
Analysts are mixed. Evercore ISI lowered the price target to $16 from $23, maintaining an Outperform rating. H.C. Wainwright raised the price target to $47 from $39, citing FDA approval of a new treatment. The sentiment is cautiously optimistic but not overwhelmingly bullish.
